The HER2/neu (erbB2) polymorphism, body mass index, and the risk of endometrial cancer

被引：0
|
作者：
Lee, J.
Tong, S.
Lee, K.
Kim, J.
Kwon, Y.
Kim, J.
Kim, Y.
Yei, J.
Do, Y.
Kwon, S.
机构：
[1] Kyung Hee Univ, EW Neo Med Ctr, Seoul, South Korea
[2] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Hallym Univ, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Seoul, South Korea
[6] Catholic Univ, Daegu Sch Med, Taegu, South Korea
[7] Keimyung Univ, Sch Med, Taegu, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.22199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22199
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MOLECULAR LANDSCAPE OF ERBB2/HER2 GENE AMPLIFICATION AMONG PATIENTS WITH ENDOMETRIAL CARCINOMA
    Nasioudis, Dimitrios
    Latif, Nawar
    Haggerty, Ashley
    Cory, Lori
    Kim, Sarah
    Morgan, Mark
    Simpkins, Fiona
    Ko, Emily
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A26 - A26
  • [22] HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
    Plum, Patrick Sven
    Gebauer, Florian
    Kraemer, Max
    Alakus, Hakan
    Berlth, Felix
    Chon, Seung-Hun
    Schiffmann, Lars
    Zander, Thomas
    Buettner, Reinhard
    Hoelscher, Arnulf Heinrich
    Bruns, Christiane Josephine
    Quaas, Alexander
    Loeser, Heike
    BMC CANCER, 2019, 19 (1)
  • [23] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Daniel Harari
    Yosef Yarden
    Oncogene, 2000, 19 : 6102 - 6114
  • [24] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Harari, D
    Yarden, Y
    ONCOGENE, 2000, 19 (53) : 6102 - 6114
  • [25] HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
    Patrick Sven Plum
    Florian Gebauer
    Max Krämer
    Hakan Alakus
    Felix Berlth
    Seung-Hun Chon
    Lars Schiffmann
    Thomas Zander
    Reinhard Büttner
    Arnulf Heinrich Hölscher
    Christiane Josephine Bruns
    Alexander Quaas
    Heike Loeser
    BMC Cancer, 19
  • [26] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
    Fumoleau, Pierre
    EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
  • [27] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [28] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
  • [29] The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer
    Lippa, Blaise
    Kauffman, Goss S.
    Arcari, Joel
    Kwan, Tricia
    Chen, Jinshan
    Hungerford, William
    Bhattacharya, Samit
    Zhao, Xumiao
    Williams, Courtney
    Xiao, Jun
    Pustilnik, Leslie
    Su, Chunyan
    Moyer, James D.
    Ma, Ling
    Campbell, Mary
    Steyn, Stefanus
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (11) : 3081 - 3086
  • [30] Repurposing erbb2 (HER2/neu) as a neoantigen target for neu-negative tumors using a novel erbb2-encoding lentivirus.
    Gabriel, Emmanuel M.
    Necela, Brian
    Bahr, Deborah
    Kaplan, Jamie
    Attwood, Kristopher
    Knutson, Keith
    CANCER RESEARCH, 2022, 82 (12)
12345